繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 精神心理 >> 精神分裂症 >> 药品推荐 >> Abilify Maintena injection(阿立哌唑长效注射剂)

Abilify Maintena injection(阿立哌唑长效注射剂)

2015-04-30 12:33:16  作者:新特药房  来源:互联网  浏览次数:183  文字大小:【】【】【
简介: 每月注射一次的长效精神分裂症药物Abilify Maintena(aripiprazole)获FDA、欧盟、加拿大批准上市2014年3月17日,欧盟推出长效版精神分裂症药物Abilify Maintena(aripiprazole,阿立哌唑),该药为每月 ...

每月注射一次的长效精神分裂症药物Abilify Maintena(aripiprazole)获FDA、欧盟、加拿大批准上市
2014年3月17日,欧盟推出长效版精神分裂症药物Abilify Maintena(aripiprazole,阿立哌唑),该药为每月一次的肌内注射(IM)剂型药物,用于口服阿立哌唑稳定病情的精神分裂症(schizophrenia)成人患者的维持治疗。
目前,Abilify Maintena已获FDA、欧盟、加拿大批准。
防止复发是治疗精神分裂症的关键。支持Abilify Maintena监管文件的关键性研究证明,在精神分裂症的长期治疗中,与安慰剂相比,Abilify Maintena能够降低复发的风险,而且疗效不逊色于口服阿立哌唑。
此外,Abilify Maintena具有与口服阿立哌唑类似的耐受性,同时,与安慰剂相比,Abilify Maintena在患者个人和社会功能上表现出统计学意义的显著改善,在双盲治疗阶段结束时,高达93%的患者对Abilify Maintena治疗表现出及其满意、非常满意或有点满意。
在欧洲,Abilify Maintena是唯一一种每月一次的注射剂型多巴胺D2部分激动剂,用于精神分裂症的维持治疗。
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection
1. Name of the medicinal product
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection
2. Qualitative and quantitative composition
Each vial contains 400 mg aripiprazole.
After reconstitution each ml of suspension contains 200 mg aripiprazole.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Powder and solvent for prolonged-release suspension for injection
Powder: white to off-white
Solvent: clear solution
4. Clinical particulars
4.1 Therapeutic indications
Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. 4.2 Posology and method of administration
Posology
For patients who have never taken aripiprazole, tolerability with oral aripiprazole must occur prior to initiating treatment with Abilify Maintena.
The recommended starting and maintenance dose of Abilify Maintena is 400 mg.
Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).
After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.
If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered.
Missed doses

Missed doses

If 2nd or 3rd dose is missed and time since last injection is:

Action

> 4 weeks and < 5 weeks

The injection should be administered as soon as possible and then resume monthly injection schedule.

> 5 weeks

Concomitant oral aripiprazole should be restarted for 14 days with next administered injection and then resume monthly injection schedule.

If 4th or subsequent doses are missed (i.e., after attainment of steady state) and time since last injection is:

Action

> 4 weeks and < 6 weeks

The injection should be administered as soon as possible and then resume monthly injection schedule.

> 6 weeks

Concomitant oral aripiprazole should be restarted for 14 days with next administered injection and then resume monthly injection schedule.

Special populations
Elderly patients
The safety and efficacy of Abilify Maintena in the treatment of schizophrenia in patients 65 years of age or older has not been established (see section 4.4).
Renal impairment
No dosage adjustment is required for patients with renal impairment (see section 5.2).
Hepatic impairment
No dosage adjustment is required for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients requiring cautious dosing, oral formulation should be preferred (see section 5.2).
Known CYP2D6 poor metabolisers
In patients who are known to be CYP2D6 poor metabolisers, the starting and maintenance dose should be 300 mg. When used concomitantly with strong CYP3A4 inhibitors the dose should be reduced to 200 mg (see section 4.5).
Dose adjustments due to interactions
Dosage adjustments should be done in patients taking concomitant strong CYP3A4 inhibitors or strong CYP2D6 inhibitors for more than 14 days. If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be increased to the previous dose (see section 4.5). In case of adverse reactions despite dose adjustments of Abilify Maintena, the necessity of concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.
Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels (see section 4.5).
Dose adjustments of Abilify Maintena in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14 days

Adjusted dose

Patients taking 400 mg of Abilify Maintena

Strong CYP2D6 or strong CYP3A4 inhibitors

300 mg

Strong CYP2D6 and strong CYP3A4 inhibitors

200 mg

CYP3A4 inducers

Avoid use

Patients taking 300 mg of Abilify Maintena

Strong CYP2D6 or strong CYP3A4 inhibitors

200 mg

Strong CYP2D6 and strong CYP3A4 inhibitors

160 mg

CYP3A4 inducers

Avoid use

Paediatric population
The safety and efficacy of Abilify Maintena in children and adolescents aged 0-17 years have not been established. No data are available.
Method of administration
Abilify Maintena is only intended for intramuscular use and should not be administered intravenously or subcutaneously. It should only be administered by a healthcare professional. The suspension should be injected immediately after reconstitution but can be stored below 25 °C for up to 4 hours in the vial. The suspension should be injected slowly as a single injection (doses must not be divided) into the gluteal or deltoid muscle. Care should be taken to avoid inadvertent injection into a blood vessel. Sites of injections should be rotated between the two gluteal or deltoid muscles.
The recommended needle for gluteal administration is a 38 mm (1.5 inch), 22 gauge hypodermic safety needle. For obese patients (Body mass index > 28 kg/m2), a 50 mm (2 inch), 21 gauge hypodermic safety needle should be used.
The recommended needle for deltoid administration is a 25 mm (1 inch), 23 gauge hypodermic safety needle. For obese patients, a 38 mm (1.5 inch), 22 gauge hypodermic safety needle should be used (see section 6.6).
The powder and solvent vials are for single-use only.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.
Suicidality
The occurrence of suicidal behaviour is inherent in psychotic illnesses, and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). Close supervision of high risk patients should accompany antipsychotic treatment.
Cardiovascular disorders
Abilify Maintena should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.
Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Abilify Maintena and preventive measures undertaken (see section 4.8).
QT prolongation
In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).
Tardive dyskinesia
In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on Abilify Maintena, dose reduction or discontinuation of should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.
Neuroleptic Malignant Syndrome (NMS)
NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicinal products, including aripiprazole, must be discontinued (see section 4.8).
Seizure
In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).
Elderly patients with dementia-related psychosis
Increased mortality
In three placebo-controlled trials of oral aripiprazole in elderly patients with psychosis associated with Alzheimer's disease (n = 938; mean age: 82.4 years; range: 56-99 years), patients treated with aripiprazole are at an increased risk of death compared to placebo. The rate of death in oral aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).
Cerebrovascular adverse reactions
In the same trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78-88 years). Overall, 1.3 % of oral aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).
Abilify Maintena is not indicated for the treatment of patients with dementia-related psychosis.
Hyperglycaemia and diabetes mellitus
Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotic medicines, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotic medicines are not available to allow direct comparisons. Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Hypersensitivity
Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole.
Weight gain
Weight gain is commonly seen in schizophrenic patients due to use of antipsychotics known to cause weight gain, co-morbidities, poorly managed life-style and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed oral aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain (see section 4.8).
Dysphagia
Oesophageal dysmotility and aspiration have been associated with antipsychotic medicinal product use, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.
Pathological gambling
Post-marketing reports of pathological gambling have been reported among patients prescribed oral aripiprazole, regardless of whether these patients had a prior history of gambling. Patients with a prior history of pathological gambling may be at increased risk and should be monitored carefully (see section 4.8).
4.5 Interaction with other medicinal products and other forms of interaction
No specific interaction studies have been performed with Abilify Maintena. The information below is obtained from studies with oral aripiprazole.
Due to its α1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.
Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).
If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.
Potential for other medicinal products to affect Abilify Maintena
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes, but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.
Quinidine and other strong CYP2D6 inhibitors
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reduction should, therefore, be applied (see section 4.2).
Ketoconazole and other strong CYP3A4 inhibitors
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2).
When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section 4.2).
Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of Abilify Maintena should be increased to the dose prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g., diltiazem) or CYP2D6 (e.g., escitalopram) are used concomitantly with this medicinal product, modest increases in plasma aripiprazole concentrations may be expected.
Carbamazepine and other CYP3A4 inducers
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when oral aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with oral aripiprazole alone.
Concomitant administration of Abilify Maintena and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects. The concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided because the blood levels of aripiprazole are decreased and may be below the effective levels.
Valproate and lithium
When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations, and, therefore, no dose adjustment is necessary when either valproate or lithium is administered with Abilify Maintena.
Potential for Abilify Maintena to affect other medicinal products
In clinical studies, oral doses of 10-30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), 2C9 (warfarin), 2C19 (omeprazole), and 3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro. Thus, Abilify Maintena is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.
When aripiprazole was administered concomitantly with lamotrigine, dextromethorphan, warfarin, omeprazole, escitalopram, or venlafaxine there was no clinically important change in concentrations of these medicinal products. Thus, no dosage adjustment of these medicinal products is required when co-administered with Abilify Maintena.
Serotonin syndrome
Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).
4.6 Fertility, pregnancy and lactation
Pregnancy
There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with Abilify Maintena. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.
Prescribers need to be aware of the long-acting properties of Abilify Maintena.
New-born infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, new-born infants should be monitored carefully (see section 4.8).
Breast-feeding
Aripiprazole is excreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Abilify Maintena therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
Aripiprazole did not impair fertility based on data from reproductive toxicity studies.
4.7 Effects on ability to drive and use machines
Abilify Maintena can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred (see section 4.8). Therefore, patients should be advised not to drive or operate machines until their individual susceptibility to this medicinal product is known. 4.8 Undesirable effects
Summary of the safety profile
The most frequently observed adverse drug reactions (ADRs) reported in ≥ 5 % of patients in two double-blind controlled clinical trials of Abilify Maintena were weight increased (9.0 %), akathisia (7.9 %), insomnia (5.8 %), and injection site pain (5.1 %).
Tabulated list of adverse reactions
The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as "not known".

Common

Uncommon

Not known

Blood and lymphatic system disorders

 

Neutropenia

Anaemia

Thrombocytopenia

Neutrophil count decreased

White blood cell count decreased

Leukopenia

Immune system disorders

 

Hypersensitivity

Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)

Endocrine disorders

 

Blood prolactin decreased

Diabetic hyperosmolar coma

Diabetic ketoacidosis

Metabolism and nutrition disorders

Weight increased

Diabetes mellitus

Weight decreased

Hyperglycaemia

Hypercholesterolaemia

Hyperinsulinaemia

Hyperlipidaemia

Hypertriglyceridaemia

Appetite disorder

Anorexia

Hyponatraemia

Psychiatric disorders

Agitation

Anxiety

Restlessness

Insomnia

Suicidal ideation

Psychotic disorder

Hallucination

Delusion

Hypersexuality

Panic reaction

Depression

Affect lability

Apathy

Dysphoria

Sleep disorder

Bruxism

Libido decreased

Mood altered

Completed suicide

Suicide attempt

Pathological gambling

Nervousness

Nervous system disorders

Extrapyramidal disorder

Akathisia

Tremor

Dyskinesia

Sedation

Somnolence

Dizziness

Headache

Dystonia

Tardive dyskinesia

Parkinsonism

Movement disorder

Psychomotor hyperactivity

Restless legs syndrome

Cogwheel rigidity

Hypertonia

Bradykinesia

Drooling

Dysgeusia

Parosmia

Neuroleptic malignant syndrome

Grand mal convulsion Serotonin syndrome

Speech disorder

Eye disorders

 

Oculogyric crisis

Vision blurred

Eye pain

 

Cardiac disorders

 

Ventricular extrasystoles

Bradycardia

Tachycardia

Electrocardiogram T wave amplitude decreased

Electrocardiogram abnormal

Electrocardiogram T wave inversion

Sudden unexplained death

Cardiac arrest

Torsades de pointes Ventricular arrhythmias

QT prolongation

Vascular disorders

 

Hypertension

Orthostatic hypotension

Blood pressure increased

Syncope

Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)

Respiratory, thoracic and mediastinal disorders

 

Cough

Oropharyngeal spasm

Laryngospasm

Aspiration pneumonia

Gastrointestinal disorders

Dry mouth

Gastrooesophageal reflux disease

Dyspepsia

Vomiting

Diarrhoea

Nausea

Abdominal pain upper

Abdominal discomfort

Constipation

Frequent bowel movement

Salivary hypersecretion

Pancreatitis

Dysphagia

Hepatobiliary disorders

 

Liver function test abnormal

Hepatic enzyme increased

Alanine aminotransferase increased

Gamma-glutamyl transferase increased

Blood bilirubin increased

Aspartate aminotransferase increased

Hepatic failure

Jaundice

Hepatitis

Alkaline phosphatase increased

Skin and subcutaneous tissue disorders

 

Alopecia

Acne

Rosacea

Eczema

Skin induration

Rash

Photosensitivity reaction

Hyperhidrosis

Musculoskeletal and connective tissue disorders

Musculoskeletal stiffness

Muscle rigidity

Muscle spasms

Muscle twitching

Muscle tightness

Myalgia

Pain in extremity

Arthralgia

Back pain

Joint range of motion decreased

Nuchal rigidity

Trismus

Rhabdomyolysis

Renal and urinary disorders

 

Nephrolithiasis

Glycosuria

Urinary retention, Urinary incontinence

Pregnancy, puerperium and perinatal conditions

   

Drug withdrawal syndrome neonatal (see section 4.6)

Reproductive system and breast disorders

Erectile dysfunction

Galactorrhoea

Gynaecomastia

Breast tenderness

Vulvovaginal dryness

Priapism

General disorders and administration site conditions

Injection site pain

Injection site induration

Fatigue

Pyrexia

Asthenia

Gait disturbance

Chest discomfort

Injection site reaction

Injection site erythema

Injection site swelling

Injection site discomfort

Injection site pruritus

Thirst

Sluggishness

Temperature regulation disorder (e.g. hypothermia, pyrexia)

Chest pain

Peripheral oedema

Investigations

Blood creatine phosphokinase increased

Blood glucose increased

Blood glucose decreased

Glycosylated haemoglobin increased

Waist circumference increased

Blood cholesterol decreased

Blood triglycerides decreased

Blood glucose fluctuation

Description of selected adverse reactions
Injection site reactions
During the double-blind, controlled phases of the two trials, injection site reactions were observed; those seen were generally mild to moderate in severity, and resolved over time. Injection site pain (incidence 5.1 %), has a median onset on day 2 after the injection and a median duration of 4 days.
In an open label study comparing bioavailability of Abilify Maintena administered in the deltoid or gluteal muscle, injection site related reactions were slightly more frequent in the deltoid muscle. The majority were mild and improved on subsequent injections. When compared to studies where Abilify Maintena was injected in the gluteal muscle, repeated occurrence of injection site pain is more frequent in the deltoid muscle.
Leukopenia
Neutropenia has been reported in the clinical program with Abilify Maintena and typically starts around day 16 after first injection, and lasts a median of 18 days.
Extrapyramidal Symptoms (EPS)
In trials in stable patients with schizophrenia, Abilify Maintena was associated with a higher frequency of EPS symptoms (18.4 %) than oral aripiprazole treatment (11.7 %). Akathisia was the most frequently observed symptom (8.2 %) and typically starts around day 10 after first injection, and lasts a median of 56 days.
Subjects with akathisia typically received anti-cholinergic medicines as treatment, primarily benzatropine mesilate and trihexyphenidyl. Less often substances such as propranolol and benzodiazepines (clonazepam and diazepam) were administered to control akathisia.
Parkinsonism events followed in frequency (6.9 % Abilify Maintena, 4.15 % oral aripiprazole 10-30mg tablets group and 3.0 % placebo, respectively).
Dystonia
Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.
Weight
During the double-blind, active-controlled phase of the 38-week trial, the incidence of weight gain of ≥ 7 % from baseline to last visit was 9.5 % for Abilify Maintena group and 11.7 % for the oral aripiprazole tablets 10-30 mg group. The incidence of weight loss of ≥ 7 % from baseline to last visit was 10.2 % for Abilify Maintena and 4.5 % for oral aripiprazole tablets 10-30 mg.
During the double-blind, placebo-controlled phase of the 52-week trial, the incidence of weight gain of ≥ 7 % from baseline to last visit was 6.4 % for the Abilify Maintena group and 5.2 % for the placebo group. The incidence of weight loss of ≥ 7 % from baseline to last visit was 6.4 % for the Abilify Maintena group and 6.7 % for the placebo group. During double-blind treatment, mean change in body weight from baseline to last visit was -0.2 kg for Abilify Maintena and -0.4 kg for placebo (p = 0.812).
Prolactin
In the double-blind active-controlled phase of the 38-week, trial, from baseline to last visit there was a mean decrease in prolactin levels in the Abilify Maintena group (−0.33 ng/ml) compared with a mean increase in the oral aripiprazole tablets 10-30 mg group (0.79 ng/ml; p < 0.01). The incidence of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) at any assessment was 5.4 % compared with 3.5 % of the patients on oral aripiprazole tablets 10-30 mg. Male patients generally had a higher incidence than female patients in each treatment group.
In the double-blind placebo-controlled phase of the 52-week trial, from baseline to last visit there was a mean decrease in prolactin levels in the Abilify Maintena group (−0.38 ng/ml) compared with a mean increase in the placebo group (1.67 ng/ml).
The incidences of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) was 1.9 % compared to 7.1 % for placebo patients.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.
4.9 Overdose
No cases of overdose associated with adverse reactions were reported in clinical studies with Abilify Maintena. Care must be taken to avoid inadvertent injection of this medicinal product into a blood vessel. Following any confirmed or suspected accidental overdose/inadvertent intravenous administration, close observation of the patient is needed and if any potentially medically serious sign or symptom develops, monitoring, which should include continuous electrocardiographic monitoring, is required. The medical supervision and monitoring should continue until the patient recovers.
A simulation of dose dumping showed that the predicted median aripiprazole concentration reaches a peak of 4500 ng/ml or approximately 9 times the upper therapeutic range. In case of dose dumping, aripiprazole concentrations are predicted to descend rapidly to the upper limit of the therapeutic window after approximately 3 days. By the 7th day, the median aripiprazole concentrations further decline to concentrations following an IM depot dose with no dose dumping. While overdose is less likely with parenteral than oral medicinal products, reference information for oral aripiprazole overdose is presented below.
Signs and symptoms
In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg (41 times highest recommended daily aripiprazole dose) with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.
Management of overdose
Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.
The possibility of multiple medicinal product involvement should be considered. Therefore, cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.
Haemodialysis
Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12
Mechanism of action
It has been proposed that aripiprazole's efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2A receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity. Aripiprazole exhibits high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and has moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic, and histamine H1 receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for cholinergic muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.
Aripiprazole oral doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.
Further information on clinical trials:
Maintenance treatment of schizophrenia in adults
The efficacy of Abilify Maintena in the maintenance treatment of patients with schizophrenia was established in two randomised, double-blind trials.
The pivotal trial was a 38 week, randomised, double-blind, active-controlled trial designed to establish the efficacy, safety, and tolerability of this medicinal product administered as monthly injections compared to once daily oral aripiprazole tablets 10-30 mg as maintenance treatment in adult patients with schizophrenia. This trial consisted of a screening phase and 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and Double-blind, Active-controlled Phase.
Six-hundred and sixty two patients eligible for the 38-week Double-Blind, Active-Controlled Phase were randomly assigned in a 2:2:1 ratio to double-blind treatment to one of 3 treatment groups: 1) ABILIFY MAINTENA 2) the stabilisation dose of oral aripiprazole 10-30 mg, or 3) aripiprazole Long-Acting Injectable 50 mg/25 mg. The aripiprazole Long-Acting Injectable 50 mg/25 mg dose was included as a low dose aripiprazole group to test assay sensitivity for the non-inferiority design.
The results of analysis of the primary efficacy endpoint, the estimated proportion of patients experiencing impending relapse by end of Week 26 of the Double-blind, Active-controlled Phase, showed that Abilify Maintena 400 mg/300 mg is non-inferior to aripiprazole oral tablets 10-30 mg.
The estimated relapse rate by end of Week 26 was 7.12 % in the Abilify Maintena group, and 7.76 % in the oral aripiprazole tablets 10-30 mg group, a difference of -0.64 %. The 95 % CI (-5.26, 3.99) for the difference in the estimated proportion of patients experiencing impending relapse by end of Week 26 excluded the predefined non-inferiority margin, 11.5 %. Therefore, Abilify Maintena is non-inferior to the aripiprazole oral tablets 10-30 mg formulation.
The estimated proportion of patients experiencing impending relapse by end of Week 26 for the Abilify Maintena group was 7.12 %, which was statistically significantly lower than in the aripiprazole Long-Acting Injectable 50 mg/25 mg group (21.80 %; p = 0.0006). Thus, superiority of Abilify Maintena over the aripiprazole Long-Acting Injectable 50 mg/25 mg was established and the validity of the trial design was confirmed.
The Kaplan-Meier curves of the time from randomisation to impending relapse during the 38-week, double-blind treatment phase for Abilify Maintena, oral aripiprazole 10-30 mg group, and aripiprazole Long-Acting Injectable 50 mg/25 mg groups are shown in Figure 1.
Figure 1 Kaplan-Meier Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending Relapse

NOTE: ARIP IMD 400/300 mg = Abilify Maintena; ARIP 10-30 mg = oral aripiprazole; ARIP IMD 50/25 mg = Long-acting Injectable
Further, the non-inferiority of Abilify Maintena compared to oral aripiprazole 10-30 mg is supported by the results of the analysis of Positive and Negative Syndrome Scale for Schizophrenia (PANSS).
Table 1 PANSS Total Score – Change From Baseline to Week 38-LOCF:
Randomised Efficacy Sample a, b

PANSS Total Score – Change From Baseline to Week 38-LOCF:

Randomised Efficacy Sample a, b

 

Abilify Maintena 400 mg/300 mg

(n = 263)

Oral aripiprazole

10-30 mg/day

(n = 266)

Aripiprazole Long-Acting Injectable 50 mg/25 mg

(n = 131)

Mean baseline (SD)

57.9 (12.94)

56.6 (12.65)

56.1 (12.59)

Mean change (SD)

-1.8 (10.49)

0.7 (11.60)

3.2 (14.45)

P-value

NA

0.0272

0.0002

a: Negative change in score indicates improvement.
b: Only patients having both baseline and at least one post baseline were included. P-values were derived from comparison for change from baseline within analysis of covariance model with treatment as term and baseline as covariate.
The second trial was a 52-week, randomised, withdrawal, double-blind, trial conducted in US adult patients with a current diagnosis of schizophrenia. This trial consisted of a screening phase and 4 treatment phases: Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation requirement in the Oral Stabilisation Phase were assigned to receive, in a single-blind fashion, Abilify Maintena and began an Abilify Maintena Stabilisation Phase for a minimum of 12 weeks and a maximum of 36 weeks. Patients eligible for the Double-blind, Placebo-controlled Phase were randomly assigned in a 2:1 ratio to double-blind treatment with Abilify Maintena or placebo, respectively
The final efficacy analysis included 403 randomised patients and 80 exacerbations of psychotic symptoms/impending relapse events. In the placebo arm 39,6% of the patients had progressed to impending relapse, whilst in the Abilify Maintena impending relapse occurred in 10% of the patients; thus patients in the placebo group had a 5.03-fold greater risk of experiencing impending relapse.
Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with Abilify Maintena in all subsets of the paediatric population in schizophrenia (see section 4.2).
5.2 Pharmacokinetic properties
Absorption
Aripiprazole absorption into the systemic circulation is slow and prolonged following Abilify Maintena administration due to low solubility of aripiprazole particles.
The average absorption half-life of Abilify Maintena is 28 days. Absorption of aripiprazole from the IM depot formulation was complete relative to the IM standard (immediate-release) formulation. The dose adjusted Cmax values for the depot formulation were approximately 5% of Cmax from IM standard formulation.
Following a single dose administration of Abilify Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was similar for both injection sites, but the rate of absorption (Cmax) was higher following administration to the deltoid muscle.
Following multiple intramuscular doses, the plasma concentrations of aripiprazole gradually rise to a maximum plasma concentration at a median tmax of 7 days for the gluteal muscle and 3 days for the deltoid muscle.
Steady state concentrations for the typical subject were attained by the fourth dose for both sites of administration.
Less than dose-proportional increases in aripiprazole and dehydro-aripiprazole concentrations and AUC parameters are observed after monthly Abilify Maintena injections of 300 mg to 400 mg.
Distribution
Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.
Biotransformation
Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. After multiple dose administration of Abilify Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1-32.5 % of aripiprazole AUC in plasma.
Elimination
After administration of multiple dose of 400 mg or 300 mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9 days presumably due to absorption rate-limited kinetics.
Following a single oral dose of [14C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.
Pharmacokinetics in special patient groups
CYP2D6 poor metabolisers
Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71 L/h in extensive metabolisers of CYP2D6 and approximately 1.88 L/h (approximately 50 % lower) in poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).
Elderly
After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects. Similarly, there was no detectable effect of age in a population pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.
Gender
After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects. Similarly, there was no clinically relevant effect of gender in a population pharmacokinetic analysis of Abilify Maintena in clinical trials in patients with schizophrenia.
Smoking
Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.
Race
Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.
Renal impairment
In a single-dose study with oral administration of aripiprazole, the pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to that in young healthy subjects.
Hepatic impairment
A single-dose study with oral administration of aripiprazole to subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
5.3 Preclinical safety data
The toxicological profile for aripiprazole administered to experimental animals by intramuscular injection is generally similar to that seen following oral administration at comparable plasma levels. With intramuscular injection, however an inflammatory response was seen at the injection site, and consisted of granulomatous inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling) and, in monkeys, fibrosis. These effects gradually resolved with discontinuation of dosing.
Non-clinical safety data for orally administered aripiprazole revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, and carcinogenic potential.
Oral aripiprazole
For oral aripiprazole, toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity in rats after 104 weeks of oral administration at approximately 3 to 10 times the mean steady-state AUC at the maximum recommended human dose and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at approximately 10 times the mean steady-state AUC at the maximum recommended human dose. The highest non-tumorigenic exposure in female rats was approximately 7 times the human exposure at the recommended dose.
An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day or approximately16 to 81 times the maximum recommended human dose based on mg/m2.
However, the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of in vitro solubility.
In repeat dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse events on development.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies.
Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures approximately 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.
6. Pharmaceutical particulars
6.1 List of excipients
Powder
Carmellose sodium
Mannitol
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide
Solvent
Water for injections
6.2 Incompatibilities
Not applicable 6.3 Shelf life
3 years
After reconstitution
Chemical and physical in-use stability has been demonstrated for 4 hours at 25°C. From a microbiological point of view, unless the method of opening/ reconstitution precludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of user. Shake the vial vigorously for at least 60 seconds to re-suspend prior to injection. Do not store the reconstituted suspension in the syringe.
6.4 Special precautions for storage
Do not freeze.
For storage conditions after reconstitution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
400 mg powder:
Type-I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
Solvent:
2 ml Type-1 glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
Single pack
Each single pack containing one vial of powder, 2 ml vial of solvent, one 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch) 21 gauge, hypodermic safety needle with needle protection device, one 3 ml disposable syringe with luer lock tip, one vial adapter and three hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm (1.5 inch) 22 gauge and one 50 mm (2 inch) 21 gauge.
Multipack
Bundle pack of 3 single packs.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Step 1: Preparation prior to reconstitution of the powder.
a) Lay out and confirm that components listed below are provided:
- Abilify Maintena package leaflet and instructions for healthcare professionals
- Vial of powder
- 2 ml vial of solvent
Important: the solvent vial contains an overfill.
- One 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch) 21 gauge hypodermic safety needle with needle protection device
- One 3 ml disposable syringe with luer lock tip
- One vial adapter
- One 25 mm (1 inch) 23 gauge hypodermic safety needle with needle protection device
- One 38 mm (1.5 inch) 22 gauge hypodermic safety needle with needle protection device
- One 50 mm (2 inch) 21 gauge hypodermic safety needle with needle protection device
- Syringe and needle instructions
Step 2: Reconstitution of the powder
a) Remove the solvent and powder vial caps and wipe the tops with a sterile alcohol swab.
b) Using the syringe with pre-attached needle, withdraw the pre-determined solvent volume from the vial of the solvent into the syringe.
400 mg vial:
Add 1.9 ml solvent to reconstitute the powder
A small amount of residual solvent will remain in the vial following withdrawal. Any excess should be discarded.


c) Slowly inject the solvent into the vial containing the powder.
d) Withdraw air to equalise the pressure in the vial by pulling back slightly on the plunger.


e) Subsequently, remove the needle from the vial.
Engage the needle safety device by using the one-handed technique.
Gently press the sheath against a flat surface until the needle is firmly engaged in the needle protection sheath.
Visually confirm that the needle is fully engaged into the needle protection sheath, and discard.


Cover


Discard
f) Shake the vial vigorously for 30 seconds until the suspension appears uniform.


g) Visually inspect the reconstituted suspension for particulate matter and discolouration prior to administration. The reconstituted medicine is a white to off-white, fluid suspension. Do not use if reconstituted suspension contains particulate matter or any discolouration.
h) If the injection is not performed immediately after reconstitution, keep the vial below 25 °C for up to 4 hours and shake it vigorously for at least 60 seconds to re-suspend prior to injection.
i) Do not store the reconstituted suspension in the syringe.
Step 3: Preparation prior to injection
a) Remove the cover, but not the adapter from the package.
b) Using the vial adapter package to handle the vial adapter, attach the pre-packaged luer lock syringe to the vial adapter.


c) Use the luer lock syringe to remove the vial adapter from the package and discard the vial adapter package. Do not touch the spike tip of the adapter at any time.


d) Determine the recommended volume for injection.

Abilify Maintena 400 mg Vial

Dose

Volume to Inject

400 mg

2.0 ml

300 mg

1.5 ml

200 mg

1.0 ml

160 mg

0.8 ml

e) Wipe the top of the vial of the reconstituted suspension with a sterile alcohol swab.
f) Place and hold the vial of the reconstituted suspension on a hard surface. Attach the adapter-syringe assembly to the vial by holding the outside of the adapter and pushing the adapter's spike firmly through the rubber stopper, until the adapter snaps in place.
g) Slowly withdraw the recommended volume from the vial into the luer lock syringe to allow for injection.
A small amount of excess product will remain in the vial.

Step 4: Injection procedure
a) Detach the luer lock syringe containing the recommended volume of reconstituted Abilify Maintena suspension from the vial.
b) Select one of the following hypodermic safety needles depending on the injection site and patient's weight and attach the needle to the luer lock syringe containing the suspension for injection. Ensure the needle is firmly seated on the needle protection device with a push and clockwise twist and then pull the needle cap straight away from the needle.

Body type

Injection site

Needle size

Non-obese

Deltoid

25 mm (1 inch) 23 gauge

Gluteal

38 mm (1.5 inch) 22 gauge

Obese

Deltoid

38 mm (1.5 inch) 22 gauge

Gluteal

50 mm (2 inch) 21 gauge

c) Slowly inject the recommended volume as a single intramuscular injection into the gluteal or deltoid muscle. Do not massage the injection site. Care must be taken to avoid inadvertent injection into the blood vessel. Do not inject into an area with signs of inflammation, skin damage, lumps and/or bruises.
For deep intramuscular gluteal or deltoid injection only.


Remember to rotate sites of injections between the two gluteal or deltoid muscles. Look for signs or symptoms of inadvertent intravenous administration.
Step 5: Procedures after injection
a) Engage the needle safety device as described in Step 2 e). Dispose of the vials, adapter, needles, and syringe appropriately after injection.
The powder and solvent vials are for single-use only.


7. Marketing authorisation holder
Otsuka Pharmaceutical Europe Ltd.
Gallions, Wexham Springs, Framewood Road,
Wexham, SL3 6PJ - United Kingdom
8. Marketing authorisation number(s)
EU/1/13/882/002
EU/1/13/882/004
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation: 15. November 2013
10. Date of revision of the text
03/2015
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
www.oneyao.net
www.120ty.net


欧洲包装


美国包装


2014年5月2日,灵北(Lundbeck)和大冢(Otsuka)宣布,FDA已接受审查长效版精神分裂症药物Abilify Maintena(aripiprazole,阿立哌唑)的补充新药申请(sNDA),sNDA的提交意在扩大Abilify Maintean的药物标签,使该药更广泛的用于处于急性期的精神分裂症患者的治疗。
根据处方药用户收费法(PDUFA),FDA已设定Abilify Maintena审查目标日期为2014年12月7日。
Abilify Maintena sNDA的提交,是基于在住院并经历急性期发作的精神分裂症患者中开展的一项为期12周的临床试验的数据。该项研究达到了改善阳性和阴性症状量表评分表(PANSS)总分的主要疗效终点(p<0.0001)。
此外,研究数据还表明,Abilify Maintena也达到了改善临床总体印象-严重度(CGI-S评分)的关键次要终点(p<0.0001)。
关于Abilify Maintena:
Abilify Maintena(aripiprazole,阿立哌唑)是一种长效版精神分裂症药物,该药为每月一次的肌内注射(IM)剂型药物,用于口服阿立哌唑稳定病情的精神分裂症(schizophrenia)成人患者的维持治疗。目前,Abilify Maintena已获FDA、欧盟、加拿大批准。
防止复发是治疗精神分裂症的关键。支持Abilify Maintena监管文件的关键性研究证明,在精神分裂症的长期治疗中,与安慰剂相比,Abilify Maintena能够降低复发的风险,而且疗效不逊色于口服阿立哌唑.

责任编辑:admin


相关文章
Abilify Maintena(阿立哌唑缓释注射悬浮液/预填充注射器)
美国FDA批准第一个仿制药Abilify治疗精神病
阿立哌唑缓释混悬液注射|Abilify Maintena(aripiprazole monohydrate)
安立复崩解片,阿立哌唑|ABILIFY DISCMELT(ARIPIPRAZOLE)
安立复片剂ABILIFY TABLET(ARIPIPRAZOLE,阿立哌唑)
阿立哌唑片剂Abilify (Aripiprazole Tablets)
阿立哌唑与氟哌啶醇治疗首发精神分裂症效果比较
齐拉西酮与阿立哌唑治疗首发精神分裂症对照研究
阿立哌唑与舒必利治疗以阴性症状为主的精神分裂症对照观察
阿立哌唑与氯米帕明治疗强迫症的疗效
 

最新文章

更多

· ABILIFY injection(阿立...
· ABILIFY syringe(阿立哌...
· 依匹哌唑片|REXULTI(BRE...
· Abilify Maintena(阿立...
· 阿立哌唑片|Abilify(Ari...
· ABILIFY oral solution ...
· ABILIFY OD tablets(阿...
· ZYPADHERA(双羟萘酸奥氮...
· Abilit(舒必利胶囊/片/...
· LOSIZOPILON FINE GRANU...

推荐文章

更多

· ABILIFY injection(阿立...
· ABILIFY syringe(阿立哌...
· 依匹哌唑片|REXULTI(BRE...
· Abilify Maintena(阿立...
· 阿立哌唑片|Abilify(Ari...
· ABILIFY oral solution ...
· ABILIFY OD tablets(阿...
· ZYPADHERA(双羟萘酸奥氮...
· Abilit(舒必利胶囊/片/...
· LOSIZOPILON FINE GRANU...

热点文章

更多

· 依匹哌唑片|REXULTI(BRE...
· ABILIFY injection(阿立...
· Abilify Maintena(阿立...
· ABILIFY syringe(阿立哌...